FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 335:1836-1837 December 12, 1996 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Bisphosphonates are drugs that inhibit bone turnover by decreasing the resorption of bone. They do this both directly, by inhibiting the recruitment and function of osteoclasts (the bone-resorbing cells), and indirectly, by stimulating osteoblasts (the bone-forming cells), to produce an inhibitor of osteoclast formation. Bisphosphonates may also shorten the life span of osteoclasts. The bisphosphonate compounds available in at least one country include etidronate, clodronate, pamidronate, tiludronate, alendronate, and ibandronate. Although these compounds differ markedly in potency, they share common properties: they are poorly absorbed from the gastrointestinal tract and are concentrated in bone, where they remain until the bone . . . [Full Text of this Article]

References

This article has been cited by other articles:

• Pandya, N A, Meller, S T, MacVicar, D, Atra, A A, Pinkerton, C R (2001). Vertebral compression fractures in acute lymphoblastic leukaemia and remodelling after treatment. Arch. Dis. Child. 85: 492-493 [Abstract] [Full Text]  
• Hidalgo, M., Eckhardt, S. G. (2001). Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy. JNCI J Natl Cancer Inst 93: 178-193 [Abstract] [Full Text]  
• Guise, T. A., Mundy, G. R. (1998). Cancer and Bone. Endocr. Rev. 19: 18-54 [Abstract] [Full Text]